CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - FRA:AFX - DE0005313704 - Common Stock
45.22 EUR
-0.64 (-1.4%)
We assign a fundamental rating of 4 out of 10 to AFX. AFX was compared to 62 industry peers in the Health Care Equipment & Supplies industry. AFX has only an average score on both its financial health and profitability. AFX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
AFX had a positive operating cash flow in the past year.
Each year in the past 5 years AFX has been profitable.
Each year in the past 5 years AFX had a positive operating cash flow.
1.2 Ratios
AFX has a better Return On Assets (4.49%) than 62.90% of its industry peers.
AFX has a Return On Equity of 7.51%. This is comparable to the rest of the industry: AFX outperforms 59.68% of its industry peers.
The Return On Invested Capital of AFX (4.74%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for AFX is in line with the industry average of 8.76%.
The 3 year average ROIC (9.30%) for AFX is well above the current ROIC(4.74%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROIC | 4.74% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
1.3 Margins
The Profit Margin of AFX (7.19%) is comparable to the rest of the industry.
AFX's Profit Margin has declined in the last couple of years.
The Operating Margin of AFX (8.55%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AFX has declined.
With a Gross Margin value of 52.43%, AFX perfoms like the industry average, outperforming 43.55% of the companies in the same industry.
AFX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% |
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
The number of shares outstanding for AFX has been reduced compared to 1 year ago.
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
The debt/assets ratio for AFX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.39 indicates that AFX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.39, AFX is in line with its industry, outperforming 56.45% of the companies in the same industry.
The Debt to FCF ratio of AFX is 7.17, which is on the high side as it means it would take AFX, 7.17 years of fcf income to pay off all of its debts.
AFX has a Debt to FCF ratio of 7.17. This is comparable to the rest of the industry: AFX outperforms 48.39% of its industry peers.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AFX (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Altman-Z | 3.39 |
ROIC/WACC0.69
WACC6.87%
2.3 Liquidity
A Current Ratio of 2.04 indicates that AFX has no problem at all paying its short term obligations.
AFX has a Current ratio of 2.04. This is comparable to the rest of the industry: AFX outperforms 59.68% of its industry peers.
AFX has a Quick Ratio of 1.17. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AFX (1.17) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.35% yearly.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.50%.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
3.2 Future
Based on estimates for the next years, AFX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.18% on average per year.
AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.71% yearly.
EPS Next Y-14.32%
EPS Next 2Y3.4%
EPS Next 3Y9.01%
EPS Next 5Y14.18%
Revenue Next Year6.27%
Revenue Next 2Y5.68%
Revenue Next 3Y6.2%
Revenue Next 5Y6.71%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 26.44, AFX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than 64.52% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.08, AFX is valued at the same level.
A Price/Forward Earnings ratio of 21.04 indicates a rather expensive valuation of AFX.
AFX's Price/Forward Earnings is on the same level as the industry average.
AFX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.09.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.44 | ||
| Fwd PE | 21.04 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AFX is valued a bit cheaper than the industry average as 70.97% of the companies are valued more expensively.
The rest of the industry has a similar Price/Free Cash Flow ratio as AFX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.76 | ||
| EV/EBITDA | 13.63 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)11.27
EPS Next 2Y3.4%
EPS Next 3Y9.01%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.27%, AFX has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.23, AFX pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.30, AFX's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.27% |
5.2 History
On average, the dividend of AFX grows each year by 15.07%, which is quite nice.
Dividend Growth(5Y)15.07%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
33.69% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
The dividend of AFX is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.69%
EPS Next 2Y3.4%
EPS Next 3Y9.01%
FRA:AFX (10/27/2025, 7:00:00 PM)
45.22
-0.64 (-1.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners22.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.04B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.42 (22.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.27% |
Yearly Dividend1.11
Dividend Growth(5Y)15.07%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.12%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.7%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.44 | ||
| Fwd PE | 21.04 | ||
| P/S | 1.86 | ||
| P/FCF | 48.76 | ||
| P/OCF | 20.68 | ||
| P/B | 1.95 | ||
| P/tB | 10.43 | ||
| EV/EBITDA | 13.63 |
EPS(TTM)1.71
EY3.78%
EPS(NY)2.15
Fwd EY4.75%
FCF(TTM)0.93
FCFY2.05%
OCF(TTM)2.19
OCFY4.84%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)11.27
Graham Number29.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROCE | 6.52% | ||
| ROIC | 4.74% | ||
| ROICexc | 4.83% | ||
| ROICexgc | 12.2% | ||
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% | ||
| FCFM | 3.82% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Debt/EBITDA | 1.68 | ||
| Cap/Depr | 73.33% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 13.7 | ||
| Cash Conversion | 57.69% | ||
| Profit Quality | 53.21% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 3.39 |
F-Score4
WACC6.87%
ROIC/WACC0.69
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-14.32%
EPS Next 2Y3.4%
EPS Next 3Y9.01%
EPS Next 5Y14.18%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.27%
Revenue Next 2Y5.68%
Revenue Next 3Y6.2%
Revenue Next 5Y6.71%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year57.06%
EBIT Next 3Y26.22%
EBIT Next 5Y20.52%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 4 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 2 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 26.44 and the Price/Book (PB) ratio is 1.95.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 5 / 10.